What is the appropriate post‑exposure prophylaxis (PEP) regimen for a 27‑year‑old male who may have been exposed to HIV?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Post-Exposure Prophylaxis (PEP) Regimen for a 27-Year-Old Male

For a 27-year-old male with possible HIV exposure within 72 hours, initiate a 28-day course of either bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as a single-tablet regimen OR dolutegravir plus (tenofovir alafenamide OR tenofovir disoproxil fumarate) plus (emtricitabine OR lamivudine) as soon as possible 1.

Critical Timing and Indications

PEP must be initiated within 72 hours of exposure—this is a medical emergency requiring immediate action 1. The first dose should be given as soon as possible after the exposure event, as efficacy decreases with time.

When to Prescribe PEP:

  • Definitely prescribe if exposure occurred ≤72 hours ago AND the source either:

    • Has confirmed HIV without sustained viral suppression, OR
    • Has unknown HIV status or unknown viral suppression status 1

  • Case-by-case determination if exposure occurred ≤72 hours ago but source HIV status is completely unknown 1

  • Do NOT prescribe if:

    • Exposure was >72 hours ago
    • Source is known HIV-negative
    • Exposure presents no substantial risk (e.g., oral-genital contact, intact condom use)
    • Patient is already taking PrEP as recommended AND source has sustained viral suppression 1

Preferred Regimens (2025 CDC Guidelines)

The two preferred options are equally recommended 1:

Option 1: Single-Tablet Regimen

  • Bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg (BIC/FTC/TAF)
  • One tablet daily for 28 days
  • Advantage: Single pill, once daily, excellent tolerability

Option 2: Multi-Component Regimen

  • Dolutegravir 50mg once daily PLUS
  • (Tenofovir alafenamide 25mg OR tenofovir disoproxil fumarate 300mg) once daily PLUS
  • (Emtricitabine 200mg OR lamivudine 300mg) once daily
  • All for 28 days
  • Advantage: Flexibility for drug interactions or comorbidities

Pre-Treatment Assessment

Before prescribing, rapidly assess 1:

  • Renal function: If creatinine clearance <30 mL/min, avoid TAF/TDF; adjust regimen
  • Hepatic function: Significant dysfunction may require regimen modification
  • Current medications: Check for drug interactions (particularly with dolutegravir and acid-reducing agents, certain anticonvulsants)
  • Allergies: Document any prior antiretroviral allergies
  • Pregnancy status: Both regimens are safe in pregnancy, but document
  • Prior PrEP exposure: If long-acting injectable cabotegravir in past 12 months, obtain HIV NAT test in addition to standard testing 1

Laboratory Testing Protocol

At Initial Visit (Before First Dose):

  • Rapid HIV test AND/OR laboratory-based HIV Ag/Ab combination test 1
  • If recent long-acting injectable PrEP exposure: Add diagnostic HIV NAT 1
  • Baseline creatinine, hepatic function panel
  • Hepatitis B and C screening
  • Pregnancy test if applicable

During Treatment:

  • Week 4-6: HIV Ag/Ab test PLUS diagnostic HIV NAT 1
    • May defer if PEP started within 24 hours AND no missed doses 1
  • Assess adherence and tolerability

Post-Treatment:

  • Week 12: Final HIV Ag/Ab test PLUS diagnostic HIV NAT 1

Critical Implementation Points

Stop PEP immediately if the source is determined to be HIV-negative at any point during the 28-day course 1.

Common pitfalls to avoid:

  • Delaying initiation while awaiting source testing—start immediately and stop later if source is negative
  • Prescribing PEP beyond 72 hours (insufficient evidence of benefit)
  • Inadequate adherence counseling—completion rates directly impact efficacy
  • Missing drug interaction screening, particularly with over-the-counter medications

Tolerability and Adherence

Contemporary antiretroviral regimens are significantly safer and more tolerable than older PEP regimens 1. The recommended regimens have excellent safety profiles for time-limited 28-day exposure. Common side effects include:

  • Mild gastrointestinal symptoms (nausea, diarrhea)
  • Headache
  • Fatigue

These typically resolve within the first week and rarely require discontinuation.

Transition to PrEP

If this patient has ongoing or anticipated repeat HIV exposures, transition directly from PEP to PrEP 1. This involves:

  • HIV testing at completion of 28-day PEP course
  • If negative, immediately start daily oral TDF/FTC or TAF/FTC for ongoing prevention 2, 1
  • This prevents the need for repeated PEP courses and provides continuous protection

The 2025 CDC guidelines represent the most current evidence-based approach, with both BIC/FTC/TAF and DTG-based regimens newly recommended as preferred options based on their superior tolerability, once-daily dosing, and high barrier to resistance 1.

References

Related Questions

If a patient is exposed to blood on intact skin after a fight and the source's HIV status is unknown, is HIV post‑exposure prophylaxis indicated?
As a male who kissed a partner, received oral sex, and briefly performed oral‑anal contact, what is the risk of HIV transmission to me given that the partner is HIV‑negative but his pre‑exposure prophylaxis (PrEP) status is unknown?
What is the recommended HIV post‑exposure prophylaxis regimen for a 17‑year‑old male who had unprotected receptive anal intercourse with a male partner last night, has never been tested for HIV, and does not know the partner’s HIV status?
Which antiretroviral (HIV) medications can cause clinically significant acid‑base disturbances, and how should these disturbances be monitored and managed?
Should I start post‑exposure prophylaxis after being sprayed with HIV‑positive bodily fluid that may have contacted mucous membranes or non‑intact skin?
What is the definition of contusio cerebri (cerebral contusion) and its pathophysiological mechanism?
What are the possible causes of jaundice in a 70-year-old morbidly obese man who suffered a stroke two weeks ago?
How should I manage a patient with elevated LDL cholesterol on ezetimibe who refuses to take a statin?
What non‑oral medication should be given as first‑line treatment for new‑onset catatonia?
What is the likely etiology and pathology of a dome‑shaped lesion with a central keratin plug?
What instructions should be given to patients on how to take doxycycline 100 mg twice daily for rosacea, especially concerning timing with food?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.